ChrysCapital-Backed Novartis India Outlines Strategy to Double Revenue in 4–5 Years
Novartis India Ltd · Transcript · 15 Sept 2026, 9:29 pm
ChrysCapital-Backed Novartis India Outlines Strategy to Double Revenue in 4–5 Years Following ChrysCapital's acquisition of a 70.68% stake, Novartis India is executing a commercial reset to double its annualized ~INR 650 crore revenue run rate over the next four to five years. Growth will be driven by direct marketing across six anchor therapies, expanding C&F points from 4 to 25, and deploying ~900 MRs. Recent moves include acquiring Pfizer’s Minipress XL (INR 228 crore MAT revenue) for INR 1,250 crore and in-licensing ophthalmology brands. Upfront quarterly investments of INR 40–50 crore will compress near-term margins before recovering to >20% within 2–3 years.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
